SHANGHAI, Oct. 19, 2020 /PRNewswire/ -- On September 24, 111, Inc. (the "Company" or "111")
entered into a strategic partnership (the "Partnership") with
Bayer Healthcare Co. Ltd. ("Bayer
Healthcare"). The two companies will collaborate on drug
commercialization initiatives in China, including the commercialization of
innovative drugs and healthcare products, including for chronic
disease management, as well as providing reliable and convenient
resources for patient education.
111's omni-channel drug commercialization platform will
supplement Bayer Healthcare's existing sales and marketing network.
By leveraging 111's vast network of pharmacies and healthcare
providers, Bayer will be able to enhance its channel management and
patient outreach capabilities, as well as increase its market
presence in a number of underserved markets in China's tier 3-6 cities.
With this partnership, 111 and Bayer Healthcare will collaborate
to improve drug availability and accessibility and the two
companies will also jointly develop a digitalized content portal
that will provide online pharmacist training and interactive
patient education content and services. A trusted platform with
reliable, easily accessible content on disease and healthcare
management plays an essential role in empowering patients and
healthcare provides to make more informed healthcare decisions.
This patient education platform will also enable patients,
especially patients with chronic diseases, such as cardiovascular
disease or oncology patients, to explore options that could
potentially deliver a better quality of life. Further, the patient
education platform will allow patients, healthcare providers, and
pharmaceutical companies to work together to create a
patient-centric healthcare management plan that focus on providing
quality service, in a manner that is convenient to the patient.
111's Co-COO, Mr. WANG Haihui commented that he is confident
that the strategic partnership between Bayer Healthcare and 111
will allow the two companies to forge a new frontier in the
delivery of healthcare products – convenient and efficient delivery
of high-quality healthcare products in a manner that fits into
everyone's busy schedules. As part of our commitment to providing a
digitally and technologically-enabled healthcare delivery platform,
111 will continue to pursue partnership opportunities with
pharmaceutical and healthcare companies to further enhance our
omni-channel drug commercialization capabilities. In addition, we
will continue to invest resources in developing a full life-cycle
health management solutions for patients and building a
comprehensive, patients-centric, healthcare management and service
platform that will digitally connect patients with their healthcare
providers.
Mr. ZHANG Jingchuan,
Head of National Pharmacy Management at Bayer
Prescription Drug Division commented that the collaboration will be
mutually beneficial as each company brings complimentary expertise.
– Bayer Healthcare's drug discovery and development prowess,
coupled with 111's omni-channel digital healthcare platform will
pave the way for improving drug accessibility and better treatment
options and outcomes to patients. Ultimately, it is a win-win
partnership, but the real winner, and the primary focus of both
companies, is always the patients we serve.
About Bayer
Bayer is a global enterprise with core competencies in the life
science fields of health care and nutrition. Its products and
services are designed to benefit people by supporting efforts to
overcome the major challenges presented by a growing and aging
global population. At the same time, the Group aims to increase its
earning power and create value through innovation and growth. Bayer
is committed to the principles of sustainable development, and the
Bayer brand stands for trust, reliability and quality throughout
the world. In fiscal 2019, the Group employed around 104,000 people
and had sales of 43.5 billion euros.
Capital expenditures amounted to 2.9 billion
euros, R&D expenses to 5.3
billion euros. For more information, go to
www.bayer.com.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
digital healthcare platform committed to digitally connecting
patients with healthcare products and services in China. The Company provides consumers with
better access to pharmaceutical products and healthcare services
directly through its online retail pharmacy, 1 Drugstore, and
indirectly through its offline virtual pharmacy network. The
Company also offers online healthcare services through its internet
hospital, 1 Clinic, which provides consumers with cost-effective
and convenient online consultation, electronic prescription
service, and patient management service. In addition, the Company's
online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop
for pharmacies to source a vast selection of pharmaceutical
products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to
better serve their customers with cloud-based services. 111 also
provides an omni-channel drug commercialization platform to its
strategic partners, which includes services such as digital
marketing, patient education, data analytics, and pricing
monitoring.
For more information on 111, please visit:
http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
Investor Relations
Email: ir@111.com.cn
111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)
GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international
View original
content:http://www.prnewswire.com/news-releases/111-inc-teams-up-with-bayer-healthcare-to-explore-the-vast-blue-ocean-of-online-healthcare-301154693.html
SOURCE 111, Inc.